VANCOUVER, British Columbia, June 05, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage ...
Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to provide an update on subsidiary Algernon NeuroScience successfully completing the highest planned single dose of ...
A Canadian-based pharmaceutical company has received approval to conduct a clinical study of the psychedelic compound DMT as a treatment for stroke. Under the plan, pharmaceutical development company ...
VLS-01 is designed to induce a short psychedelic experience, allowing for a total in-clinic treatment of 2-hours, consistent with an established commercial paradigm in interventional psychiatry VLS-01 ...
-- Expected to accelerate clinical development pathway of CYB004 for the potential treatment of anxiety disorders by nine months -- About the CYB004-E Study The CYB004-E study is an adaptive, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results